Российский консенсус по профилактике, диагностике и лечению рака желудка. Вопросы хирургического лечения

Российский консенсус по профилактике, диагностике и лечению рака желудка подготовлен по инициативе Московского клинического научного центра им А. С. Логинова ДЗМ по Дельфийской системе. Его целью явилась консолидация мнений отечественных специалистов по наиболее актуальным вопросам профилактики, скрининга, диагностики и лечения рака желудка. Междисциплинарный подход обеспечен участием ведущих гастроэнтерологов, онкологов и хирургов. В данной статье представлены ключевые нерешенные вопросы хирургического лечения рака желудка, а также позиции Российского консенсуса по ним.

1. Smyth E.C., Verheij M., Allum W., et al; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(suppl 5):v38-v49. https://doi.org/10.1093/annonc/mdw350. PMID: 27664260

2. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1–21. https://doi.org/10.1007/s10120-020-01042-y

3. Oncology., NCCN Clinical Practice Guideline in. Gastric Cancer. version 3.2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf

4. Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer. 2019;19(1):1–48. https://doi.org/10.5230/jgc.2019.19.e8. Epub 2019 Mar 19. Erratum in: J Gastric Cancer. 2019;19(3):372–373

5. Yoshida K., Kodera Y., Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol 2019;37(15):1296–1304. https://doi.org/10.1200/JCO.18.01138

6. Sasako M., Sakuramoto S., Katai H., et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29(33):4387–93. https://doi.org/10.1200/JCO.2011.36.5908

7. Noh S.H., Park S.R., Yang H.-K., et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15(12):1389–96. https://doi.org/10.1016/S1470-2045(14)70473-5

8. Van den Ende T., Ter Veer E., Machiels M., et al. The efficacy and safety of (neo) adjuvant therapy for gastric cancer: a network meta-analysis. Cancers (Basel) 2019;11(1):80. https://doi.org/10.3390/cancers11010080

9. Давыдов М.И., Абдихакимов А.Н., Полоцкий Б.Е. К вопросу о роли хирургии в лечении местно-распространенного и диссеминированного рака желудка. Анналы хирургии. 2012;2:33–41.

10. Mintziras I., Miligkos M., Wächter S., Manoharan J., Bartsch D.K. Palliative surgical bypass is superior to palliative endoscopic stenting in patients with malignant gastric outlet obstruction: systematic review and meta-analysis. Surg Endosc 2019;33(10):3153–3164. https://doi.org/10.1007/s00464-019-06955-z

11. Jang S., Stevens T., Lopez R., Bhatt A., Vargo J.J. Superiority of gastrojejunostomy over endoscopic stenting for palliation of malignant gastric outlet obstruction. Clin Gastroenterol Hepatol 2019;17(7):1295–1302.e1. https://doi.org/10.1016/j.cgh.2018.10.042

12. Jeurnink S.M., Steyerberg E.W., Vleggaar F.P., et al; Dutch SUSTENT Study Group. Predictors of survival in patients with malignant gastric outlet obstruction: a patient-oriented decision approach for palliative treatment. Dig Liver Dis 2011;43(7):548–52. https://doi.org/10.1016/j.dld.2011.01.017

13. Navarra G., Musolino C., Venneri A., De Marco M.L., Bartolotta M. Palliative antecolic isoperistaltic gastrojejunostomy: a randomized controlled trial comparing open and laparoscopic approaches. Surg Endosc 2006;20(12):1831–4. https://doi.org/10.1007/s00464-005-0454-5

14. Kumagai K., Rouvelas I., Ernberg A., et al. A systematic review and meta-analysis comparing partial stomach partitioning gastrojejunostomy versus conventional gastrojejunostomy for malignant gastroduodenal obstruction. Langenbecks Arch Surg 2016;401(6):777–85. https://doi.org/10.1007/s00423-016-1470-8

15. Lorusso D., Giliberti A., Bianco M., Lantone G., Leandro G. Stomach-partitioning gastrojejunostomy is better than conventional gastrojejunostomy in palliative care of gastric outlet obstruction for gastric or pancreatic cancer: a meta-analysis. J Gastrointest Oncol 2019;10(2):283–291. https://doi.org/10.21037/jgo.2018.10.10

16. Kim H.H., Hyung W.J., Cho G.S., et al. Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report—a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg 2010;251:417–20. https://doi.org/10.1097/SLA.0b013e3181cc8f6b

17. Qiu H., Zhou Z. [Updates and interpretation on NCCN clinical practice guidelines for gastric cancer 2017 version 5]. Zhonghua Wei Chang Wai Ke Za Zhi. 2018;21(2):160–164

18. Katai H., Mizusawa J., Katayama H., et al; Stomach Cancer Study Group of Japan Clinical Oncology Group. Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401. Gastric Cancer 2019;22(5):999–1008. https://doi.org/10.1007/s10120-019-00929-9

19. Oh Y., Kim M.S., Lee Y.T., et al. Laparoscopic total gastrectomy as a valid procedure to treat gastric cancer option both in early and advanced stage: A systematic review and meta-analysis. Eur J Surg Oncol 2020;46(1):33–43. https://doi.org/10.1016/j.ejso.2019.08.018

20. Haverkamp L., Brenkman H.J., Seesing M.F., et al; LOGICA study group. Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial). BMC Cancer 2015;15:556. https://doi.org/10.1186/s12885-015-1551-z

21. Карачун А.М., Пелипась Ю.В., Сапронов П.А., Козлов О.А., Асадчая Д.П. Проспективное нерандомизированное исследование по типу «случай контроль»: непосредственные результаты радикальных лапароскопических вмешательств при раке желудка, опыт одного центра. Вопросы онкологии 2017;63(2):247–255. https://doi.org/10.37469/0507-3758-2017-63-2-247-255.

22. Израилов Р.Е., Поморцев Б.А., Хатьков И.Е., и соавт. Проспективное многоцентровое исследование по оценке эффективности лапароскопических гастрэктомий у больных с местно-распространенными формами рака желудка. Эндоскопическая хирургия. 2019;25(5):10–17. https://doi.org/10.17116/endoskop20192505110.

23. Сажин И.В., Куликов Е.П., Сажин В.П. Открытая и лапароскопическая лимфаденэктомия в хирургическом лечении рака желудка. Хирургия. Журнал им. Н.И. Пирогова 2009;12:68–73

24. Kodera Y., Yoshida K., Kumamaru H., et al. Introducing laparoscopic total gastrectomy for gastric cancer in general practice: a retrospective cohort study based on a nationwide registry database in Japan. Gastric Cancer 2019;22(1):202– 213. https://doi.org/10.1007/s10120-018-0795-0

25. Best L.M., Mughal M., Gurusamy K.S. Laparoscopic versus open gastrectomy for gastric cancer. Cochrane Database Syst Rev. 2016;3(3):CD011389. https://doi.org/10.1002/14651858.CD011389.pub2

26. Beyer K., Baukloh A.K., Kamphues C., et al. Laparoscopic versus open gastrectomy for locally advanced gastric cancer: a systematic review and meta-analysis of randomized controlled studies. World J Surg Oncol 2019;17(1):68. https://doi.org/10.1186/s12957-019-1600-1

27. Wang S.Y., Yeh C.N., Lee H.L., et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol 2009;16(10):2738–43. https://doi.org/10.1245/s10434-009-0616-0

28. Kumazu Y., Hayashi T., Yoshikawa T., et al. Risk factors analysis and stratification for microscopically positive resection margin in gastric cancer patients. BMC Surg 2020;20(1):95. https://doi.org/10.1186/s12893-020-00744-5

29. Jung K., Park M.I., Kim S.E., Park S.J. Borrmann type 4 advanced gastric cancer: focus on the development of scirrhous gastric cancer. Clin Endosc 2016;49(4):336–45. https://doi.org/10.5946/ce.2016.057

30. Mocellin S., Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev 2015;2015(2):CD009944. https://doi.org/10.1002/14651858.CD009944.pub2

31. Fujitani K., Yang H.K., Mizusawa J., et al; REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016;17(3):309–318. https://doi.org/10.1016/S1470-2045(15)00553-7

32. Al-Batran S.E., Homann N., Pauligk C., et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol 2017;3(9):1237–1244. https://doi.org/10.1001/jamaoncol.2017.0515

33. Al-Batran S.E., Goetze T.O., Mueller D.W., et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 2017;17(1):893. https://doi.org/10.1186/s12885-017-3918-9

34. Клинические рекомендации. Рак желудка, 2020. Доступно по: https://cr.minzdrav.gov.ru/preview-cr/574_1.

35. Saiura A., Umekita N., Inoue S., et al. Clinicopathological features and outcome of hepatic resection for liver metastasis from gastric cancer. Hepatogastroenterology 2002;49(46):1062–5

36. D’Angelica M., Gonen M., Brennan M.F., et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004;240(5):808–16. https://doi.org/10.1097/01.sla.0000143245.28656.15

37. Yamada Y., Higuchi K., Nishikawa K., et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol 2015;26(1):141–148. https://doi.org/10.1093/annonc/mdu472

38. Bang Y.J., Van Cutsem E., Feyereislova A., et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687–97. https://doi.org/10.1016/S0140-6736(10)61121-X. Erratum in: Lancet 2010;376(9749):1302

39. Uggeri F., Ripamonti L., Pinotti E., et al. Is there a role for treatment-oriented surgery in liver metastases from gastric cancer? World J Clin Oncol 2020;11(7):477–494. https://doi.org/10.5306/wjco.v11.i7.477

40. Kinoshita T., Kinoshita T., Saiura A., et al. Multicentre analysis of long-term outcome after surgical resection for gastric cancer liver metastases. Br J Surg 2015;102(1):102–7. https://doi.org/10.1002/bjs.9684

41. Luo Z., Rong Z., Huang C. Surgery strategies for gastric cancer with liver metastasis. Front Oncol 2019;9:1353. https://doi.org/10.3389/fonc.2019.01353

42. Zhang K., Chen L. Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases. Ther Adv Med Oncol 2020;12:1758835920904803. https://doi.org/10.1177/1758835920904803

43. Chung I.K., Lee J.H., Lee S.H., et al. Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD Study Group multicenter study. Gastrointest Endosc 2009;69(7):1228–35. https://doi.org/10.1016/j.gie.2008.09.027

44. Gotoda T., Jung H.Y. Endoscopic resection (endoscopic mucosal resection/ endoscopic submucosal dissection) for early gastric cancer. Dig Endosc 2013;25(Suppl_1):55–63. https://doi.org/10.1111/den.12003

45. Lian J., Chen S., Zhang Y., Qiu F. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. Gastrointest Endosc 2012;76(4):763–70. https://doi.org/10.1016/j.gie.2012.06.014

46. Park Y.M., Cho E., Kang H.Y., Kim J.M. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc 2011;25(8):2666–77. https://doi.org/10.1007/s00464-011-1627-z

47. Gotoda T., Iwasaki M., Kusano C., Seewald S., Oda I. Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg 2010;97(6):868–71. https://doi.org/10.1002/bjs.7033. PMID: 20301163

48. Gotoda T., Yanagisawa A., Sasako M., et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 2000;3(4):219–225. https://doi.org/10.1007/pl00011720

49. Ahn J.Y., Jung H.Y., Choi K.D., et al. Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. Gastrointest Endosc 2011;74(3):485–93. https://doi.org/10.1016/j.gie.2011.04.038

50. Кащенко В.А. Рак желудка: практические рекомендации / В.А. Кащенко, Р.В. Орлова. – СПб.: Изд-во “X-PRINT», 2014. – 60 с.